Companies › Lumara Bio Oncologics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| [177Lu]Lu-DPI-4452 | – | Phase 1 | Clear Cell Renal Cell Cancer (ccRCC) | Jun 2027 |
| [68Ga]Ga-DPI-4452 | – | Phase 1 | Clear Cell Renal Cell Cancer (ccRCC) | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05706129 | [68Ga]Ga-DPI-4452 | Phase 1 | Clear Cell Renal Cell Cancer (ccRCC) | Oncology | Jun 2027 |
| NCT05706129 | [177Lu]Lu-DPI-4452 | Phase 1 | Clear Cell Renal Cell Cancer (ccRCC) | Oncology | Jun 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.